Drug-resistant focal epilepsy remains a significant clinical challenge, affecting approximately 30% of epilepsy patients despite treatment with standard antiseizure medications (ASMs). The condition is associated with increased morbidity, mortality, and reduced quality of life. This study addresses a critical gap in clinical decision-making by providing direct comparative effectiveness data among newer ASMs.
Study Design
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
